188 related articles for article (PubMed ID: 32325917)
21. Reversibility of cirrhotic regenerative liver nodules upon NTBC treatment in a child with tyrosinaemia type I.
Crone J; Möslinger D; Bodamer OA; Schima W; Huber WD; Holme E; Stöckler Ipsiroglu S
Acta Paediatr; 2003 May; 92(5):625-8. PubMed ID: 12839296
[TBL] [Abstract][Full Text] [Related]
22. Nitisinone in the treatment of hereditary tyrosinaemia type 1.
McKiernan PJ
Drugs; 2006; 66(6):743-50. PubMed ID: 16706549
[TBL] [Abstract][Full Text] [Related]
23. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients.
Masurel-Paulet A; Poggi-Bach J; Rolland MO; Bernard O; Guffon N; Dobbelaere D; Sarles J; de Baulny HO; Touati G
J Inherit Metab Dis; 2008 Feb; 31(1):81-7. PubMed ID: 18214711
[TBL] [Abstract][Full Text] [Related]
24. Single dose NTBC-treatment of hereditary tyrosinemia type I.
Schlune A; Thimm E; Herebian D; Spiekerkoetter U
J Inherit Metab Dis; 2012 Sep; 35(5):831-6. PubMed ID: 22307209
[TBL] [Abstract][Full Text] [Related]
25. Tyrosinemia type I: Case series with response to treatment to NTBC.
Shah I; Shah F
Indian J Gastroenterol; 2016 May; 35(3):229-31. PubMed ID: 27109516
[TBL] [Abstract][Full Text] [Related]
26. Laboratory monitoring of patients with hereditary tyrosinemia type I.
Schultz MJ; Netzel BC; Singh RH; Pino GB; Gavrilov DK; Oglesbee D; Raymond KM; Rinaldo P; Tortorelli S; Smith WE; Matern D
Mol Genet Metab; 2020 Aug; 130(4):247-254. PubMed ID: 32546364
[TBL] [Abstract][Full Text] [Related]
27. Diurnal variation of phenylalanine concentrations in tyrosinaemia type 1: should we be concerned?
Daly A; Gokmen-Ozel H; MacDonald A; Preece MA; Davies P; Chakrapani A; McKiernan P
J Hum Nutr Diet; 2012 Apr; 25(2):111-6. PubMed ID: 22168396
[TBL] [Abstract][Full Text] [Related]
28. Natural Protein Intake in Children with Phenylketonuria: Prescription vs. Actual Intakes.
Pinto A; Daly A; Rocha JC; Ashmore C; Evans S; Ilgaz F; Hickson M; MacDonald A
Nutrients; 2023 Nov; 15(23):. PubMed ID: 38068761
[TBL] [Abstract][Full Text] [Related]
29. Determinants of tyrosinaemia during nitisinone therapy in alkaptonuria.
Ranganath LR; Milan AM; Hughes AT; Davison AS; M K; Norman BP; Bou-Gharios G; Gallagher JA; Imrich R; Arnoux JB; Rudebeck M; Olsson B
Sci Rep; 2022 Sep; 12(1):16083. PubMed ID: 36167967
[TBL] [Abstract][Full Text] [Related]
30. Nitisinone: new drug. Type 1 tyrosinemia: an effective drug.
Prescrire Int; 2007 Apr; 16(88):56-8. PubMed ID: 17458044
[TBL] [Abstract][Full Text] [Related]
31. LC-MS/MS method for simultaneous determination on a dried blood spot of multiple analytes relevant for treatment monitoring in patients with tyrosinemia type I.
la Marca G; Malvagia S; Materazzi S; Della Bona ML; Boenzi S; Martinelli D; Dionisi-Vici C
Anal Chem; 2012 Jan; 84(2):1184-8. PubMed ID: 22148291
[TBL] [Abstract][Full Text] [Related]
32. Emotional and behavioral problems, quality of life and metabolic control in NTBC-treated Tyrosinemia type 1 patients.
van Vliet K; van Ginkel WG; Jahja R; Daly A; MacDonald A; De Laet C; Vara R; Rahman Y; Cassiman D; Eyskens F; Timmer C; Mumford N; Bierau J; van Hasselt PM; Gissen P; Goyens PJ; McKiernan PJ; Wilcox G; Morris AAM; Jameson EA; Huijbregts SCJ; van Spronsen FJ
Orphanet J Rare Dis; 2019 Dec; 14(1):285. PubMed ID: 31801588
[TBL] [Abstract][Full Text] [Related]
33. The Impact of a Slow-Release Large Neutral Amino Acids Supplement on Treatment Adherence in Adult Patients with Phenylketonuria.
Burlina AP; Cazzorla C; Massa P; Loro C; Gueraldi D; Burlina AB
Nutrients; 2020 Jul; 12(7):. PubMed ID: 32674279
[TBL] [Abstract][Full Text] [Related]
34. Successful treatment of severe cardiomyopathy with NTBC in a child with tyrosinaemia type I.
André N; Roquelaure B; Jubin V; Ovaert C
J Inherit Metab Dis; 2005; 28(1):103-6. PubMed ID: 15702412
[TBL] [Abstract][Full Text] [Related]
35. Metabolomics for improved treatment monitoring of phenylketonuria: urinary biomarkers for non-invasive assessment of dietary adherence and nutritional deficiencies.
Wild J; Shanmuganathan M; Hayashi M; Potter M; Britz-McKibbin P
Analyst; 2019 Nov; 144(22):6595-6608. PubMed ID: 31608347
[TBL] [Abstract][Full Text] [Related]
36. Monitoring tyrosinaemia type I: Blood spot test for nitisinone (NTBC).
Sander J; Janzen N; Terhardt M; Sander S; Gökcay G; Demirkol M; Ozer I; Peter M; Das AM
Clin Chim Acta; 2011 Jan; 412(1-2):134-8. PubMed ID: 20883679
[TBL] [Abstract][Full Text] [Related]
37. The Effect of Glycomacropeptide versus Amino Acids on Phenylalanine and Tyrosine Variability over 24 Hours in Children with PKU: A Randomized Controlled Trial.
Daly A; Evans S; Chahal S; Santra S; Pinto A; Gingell C; Rocha JC; van Spronsen F; Jackson R; MacDonald A
Nutrients; 2019 Feb; 11(3):. PubMed ID: 30823411
[No Abstract] [Full Text] [Related]
38. Tyrosinemia type 1 in Spain: mutational analysis, treatment and long-term outcome.
Couce ML; Dalmau J; del Toro M; Pintos-Morell G; Aldámiz-Echevarría L;
Pediatr Int; 2011 Dec; 53(6):985-9. PubMed ID: 21752152
[TBL] [Abstract][Full Text] [Related]
39. Evolution of tyrosinemia type 1 disease in patients treated with nitisinone in Spain.
Couce ML; Sánchez-Pintos P; Aldámiz-Echevarría L; Vitoria I; Navas V; Martín-Hernández E; García-Volpe C; Pintos G; Peña-Quintana L; Hernández T; Gil D; Sánchez-Valverde F; Bueno M; Roca I; López-Ruzafa E; Díaz-Fernández C
Medicine (Baltimore); 2019 Sep; 98(39):e17303. PubMed ID: 31574857
[TBL] [Abstract][Full Text] [Related]
40. Renal tubular function in children with tyrosinaemia type I treated with nitisinone.
Santra S; Preece MA; Hulton SA; McKiernan PJ
J Inherit Metab Dis; 2008 Jun; 31(3):399-402. PubMed ID: 18509744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
